Last reviewed · How we verify
Escitalopram, venlafaxine, lithium
Escitalopram, venlafaxine, lithium is a Antidepressant combination (SSRI + SNRI + mood stabilizer) Small molecule drug developed by K. Lieb. It is currently FDA-approved for Treatment-resistant depression, Bipolar disorder (depression phase), Major depressive disorder with augmentation.
This is a combination therapy using escitalopram (SSRI) and venlafaxine (SNRI) to enhance serotonin and norepinephrine reuptake inhibition, with lithium added for mood stabilization and augmentation.
This is a combination therapy using escitalopram (SSRI) and venlafaxine (SNRI) to enhance serotonin and norepinephrine reuptake inhibition, with lithium added for mood stabilization and augmentation. Used for Treatment-resistant depression, Bipolar disorder (depression phase), Major depressive disorder with augmentation.
At a glance
| Generic name | Escitalopram, venlafaxine, lithium |
|---|---|
| Sponsor | K. Lieb |
| Drug class | Antidepressant combination (SSRI + SNRI + mood stabilizer) |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), and lithium-responsive intracellular signaling pathways |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Escitalopram selectively inhibits serotonin reuptake, while venlafaxine inhibits both serotonin and norepinephrine reuptake, together increasing synaptic availability of these neurotransmitters. Lithium acts as a mood stabilizer through multiple mechanisms including modulation of intracellular signaling pathways and neuroprotection. This polypharmacy approach is used to treat treatment-resistant depression and bipolar disorder.
Approved indications
- Treatment-resistant depression
- Bipolar disorder (depression phase)
- Major depressive disorder with augmentation
Common side effects
- Nausea
- Headache
- Insomnia
- Sexual dysfunction
- Tremor (lithium-related)
- Polyuria/polydipsia (lithium-related)
- Weight gain
- Dizziness
Key clinical trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Treatment of Adolescent Suicide Attempters (TASA) (PHASE2, PHASE3)
- Predictors of the Outcome of Late Life Depression
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients (PHASE4)
- Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram, venlafaxine, lithium CI brief — competitive landscape report
- Escitalopram, venlafaxine, lithium updates RSS · CI watch RSS
- K. Lieb portfolio CI
Frequently asked questions about Escitalopram, venlafaxine, lithium
What is Escitalopram, venlafaxine, lithium?
How does Escitalopram, venlafaxine, lithium work?
What is Escitalopram, venlafaxine, lithium used for?
Who makes Escitalopram, venlafaxine, lithium?
What drug class is Escitalopram, venlafaxine, lithium in?
What development phase is Escitalopram, venlafaxine, lithium in?
What are the side effects of Escitalopram, venlafaxine, lithium?
What does Escitalopram, venlafaxine, lithium target?
Related
- Drug class: All Antidepressant combination (SSRI + SNRI + mood stabilizer) drugs
- Target: All drugs targeting Serotonin transporter (SERT), norepinephrine transporter (NET), and lithium-responsive intracellular signaling pathways
- Manufacturer: K. Lieb — full pipeline
- Therapeutic area: All drugs in Psychiatry / Mental Health
- Indication: Drugs for Treatment-resistant depression
- Indication: Drugs for Bipolar disorder (depression phase)
- Indication: Drugs for Major depressive disorder with augmentation
- Compare: Escitalopram, venlafaxine, lithium vs similar drugs
- Pricing: Escitalopram, venlafaxine, lithium cost, discount & access